Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in FibromyalgiaIrwin Naturals Bringing Its Household Name Brand to the Psychedelic Mental Health SpaceTryp Therapeutics Announces Inclusion in AdvisorShares Psychedelics ETFMindMed and Liechti Lab Provide Results from their Psilocybin R&D CollaborationPsyched Wellness Announces Inclusion in AdvisorShares Psychedelics Exchange Traded Fund (ETF)Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Eating DisordersPsyched Wellness Initiates a Clinical Sleep Study on Humans for a Structure/Function Claim For AME-1Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its NoveHow Will The Data Protection Ruling On Ketamine Impact Psychedelic Novel Drug Development Moving Forward?Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic AnalogsSilo Pharma Advances Psychedelic Patent PortfolioTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of FloridaMajor Psychedelic Clinical Trial Data Is Right Around The CornerPsychedelic Drug Development Companies Are Leveraging Bolt On MedTech Acquisitions To Create A More Robust Patient Care 7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their RadarNuminus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into PSilo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide PatentTryp Therapeutics Announces Q3 2021 Financial ResultsKetamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured VeteransWake Network, Inc. and the Lieber Institute for Brain Development Announce Research Collaboration

Wake Network, Inc. and the Lieber Institute for Brain Development Announce Research Collaboration

Jul 21, 2021 • 8:06 AM EDT
6 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

Wake Network, Inc., a global leader in psilocybin mushroom research, production and the developer of genomics-based integration therapies, is pleased to announce a collaboration with the Lieber Institute for Brain Development (the ” Lieber Institute “), a non-profit research Institution and an international leader in translating genetics into brain function, to develop a one-of-a-kind, genetics-based approach to psychedelic integration and clinical research on traumatic brain injury.

Wake Network, Inc. Logo (CNW Group/Wake Network, Inc.)

In the “Wake Genomics Project”, Wake and the Lieber Institute aim to co-develop a genetics-based safety screening system to ensure the most effective therapies for patients through a combination of genome mapping, machine learning, and metabolic measurement. The project is one of the most robust genetics research initiatives in the emerging psychedelics space to date.

The Lieber Institute scientists examine the role of genetics and environment in brain development and function to better understand disorders such as schizophrenia, depression, traumatic brain injury and autism. The Lieber Institute houses the largest database of genetically profiled human brains in the world. The Institute is an independent non-profit located adjacent to the Johns Hopkins Medical Campus.

“What we are seeing is a seismic shift in demand to explore psychedelic therapies. The most important area of focus for this emerging industry in order to be successful is risk mitigation at both the compound level, but also at the psychiatric level,” says Warren Needler , President of Wake. “These compounds can cause profound shifts in consciousness, and certainly sometimes with adverse results. The work that Wake and the Lieber Institute are pursuing addresses this and allows for the industry to advance safely.”

The Wake Genomics Project officially kicks off this month and is a critical component to all clinical research underway at Wake.

“Traumatic brain injury is a devastating condition with limited treatment options,” says Daniel R. Weinberger , M.D., Lieber Institute CEO & Director. “Personalized medicine that tailors treatment to a patient’s unique genetics is a promising technique for the treatment of brain injury and other psychiatric disorders. We’re excited to use the Lieber Institute’s cutting-edge genetics in brain technology to help Wake ensure its research in this area is as safe and low risk as possible.”

For more information, please visit or contact:

Wake Network, Inc. is a fungi bioscience company focused on advancing the field of psychedelic and fungi-based therapeutics to address the growing need for mental health support in medicine and society at large. Wake is currently producing fungus-derived psilocybin and medicinal mushroom products, while working on proving out their safety through proprietary genetics-based integration therapies.

The Lieber Institute for Brain Development/Maltz Research Laboratories was established in 2010 to plot a new course in biomedical research that would improve the lives of individuals affected with developmental brain disorders. The Lieber Institute is one of the only research institutions in the world focused specifically on understanding how genes and the environment influence the way our brains develop that lead to conditions such as schizophrenia, autism, bipolar disorder and related developmental brain disorders. The Lieber Institute is an independent, non-profit 501(c)(3) organization affiliated with the Johns Hopkins University School of Medicine.

Find more information about the Lieber Institute for Brain Development/Maltz Research Laboratories here: .

Caution Regarding Forward-Looking Information

This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements.

Forward looking statements are based on certain assumptions regarding the Company, including but not limited to expected growth, results of operations, performance, industry trends and growth opportunities. While the Company considers these assumptions to be reasonable based on currently available information, they may prove to be incorrect. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to: dependence on obtaining and maintaining regulatory approvals, including federal, provincial, municipal, local or other licences, to operate and expand the Company’s facilities;  the Company’s limited operating history and lack of historical profits; reliance on management; the Company’s requirements for additional financing and the effect of capital market conditions and other factors on the availability of capital; competition, including from more established or better financed competitors; the need to secure and maintain corporate alliances and partnerships, including with research and development institutions, customers and suppliers; the Company’s ability to co-develop with the Lieber Institute a genetics-based safety screening system; that any genetics-based safety screen system co-developed by the Company and the Lieber Institute will be effective in achieving its intended purpose; that the Company will conduct the clinical trials that it intends to; the ability of the Company to discover new and/or more effective options for patients to treat their conditions; the development and implementation of medical protocols and treatment standard operating procedures for the use of psychedelic therapies; the Company’s ability to successfully withstand the economic impact of COVID-19; the medical benefits, safety, efficacy, dosing and social acceptance of psychedelics; and the cultivation and harvest of psilocybe mushrooms; and any other factors or developments that may hinder the market or the Company’s growth.

These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.

SOURCE Wake Network, Inc.


Cision View original content to download multimedia:


Source: Canada Newswire (July 21, 2021 – 8:00 AM EDT)

News by QuoteMedia

Share Share - Facebook Share - Twitter


Authored By

Michael Berger


Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.